Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib,cyclophosphamide,and dexamethasone

导出

摘要 Objective To.analyze the efficacy of second-line regimens and prognostic factors in patients with firstrelapsed multiple myeloma (MM) treated with bortezomib,cyclophosphamide,and dexamethasone(BCD).Methods Clinical data were collected in firstrelapsed MM patients after BCD treatment from three tertiary hospitals in north China from July 2009 to October 2022.

作者陈苗 CHEN Miao(Dept Hematol,PUMC&CAMS,Beijing 100730)

机构地区 Dept Hematol

出处《China Medical Abstracts(Internal Medicine)》 2024年第1期56-56,共1页 中国医学文摘（内科学分册（英文版）

关键词 regimen PATIENTS RELAPSE

分类号 R733.3 [医药卫生—肿瘤]

引文网络
相关文献

1Yèssito Corine Nadège Houehanou,Armand Wanvoègbe,Luc Béhanzin,Djidjoho Arnaud Sonou,Ursule Kanhonou,Maurice Agonnoudé,David Houéto,Thierry Adoukonou.Epidemiology of Lower Extremity Artery Disease in People Living with HIV Followed at the Departmental University Hospital Center Ouémé-Plateau in 2019[J].Open Journal of Epidemiology,2023,13(4):401-411.
2都孟仪.Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia[J].China Medical Abstracts(Internal Medicine),2024,41(1):59-60.
3袁关敏.Clinical efficacy and prognosis analysis of different treatment regimens in patients with uncomplicated brucellosis[J].China Medical Abstracts(Internal Medicine),2024,41(1):24-25.
4CAO Ni-da,ZHU Xiao-hong,MA Fang-qi,XU Yan,DONG Jia-huan,QIN Meng-meng,LIU Tian-shu,ZHU Chun-chao,GUO Wei-jian,DING Hong-hua,GUO Yuan-biao,LIU Li-kun,SONG Jin-jie,WU Ji-ping,CHENG Yue-lei,ZENG Lin,ZHAO Ai-guang.Chinese Medicine Prolongs Overall Survival of Chinese Patients with Advanced Gastric Cancer: Treatment Pattern and Survival Analysis of a 20-Year Real-World Study[J].Chinese Journal of Integrative Medicine,2024,30(6):489-498.
5Hangyu Zhang,Zhou Tong,Lulu Liu,Qihan Fu,Xudong Zhu,Xiaomeng Dai,Xuanwen Bao,Weijia Fang,Yi Zheng,Peng Zhao.Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients:a randomized–controlled open-label Phase II study[J].Gastroenterology Report,2023,11(1):224-229.
6Chia-Ching Lin,Hsu-Lin Lee,Hsin-Yi Chuo,Tuo-An Chen,Ming-Yueh Liu,Li-Mien Chen.Plasmacytosis mimicking multiple myeloma in angioimmunoblastic T-cell lymphoma:A case report and review of literature[J].World Journal of Clinical Cases,2024,12(17):3226-3234.
7许雪珠.Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma:a retrospective study based on LEGEND-2[J].China Medical Abstracts(Internal Medicine),2024,41(1):57-57.
8俞腾.Efficacy and safety of fourth-generation CD19 CAR-T expressing IL7 and CCL19 along with PD-1 monoclonal antibody for relapsed or refractory large B-cell lymphoma[J].China Medical Abstracts(Internal Medicine),2024,41(1):59-59.
9崔坤平.Risk factors related to death in patients with tuberculosis complicated with sepsis in an intensive care unit[J].China Medical Abstracts(Internal Medicine),2024,41(1):25-26.
10Yuanyuan Yuan,Boyu An,Shuyu Xie,Wei Qu,Haihong Hao,Lingli Huang,Wanhe Luo,Jixiang Liang,Dapeng Peng.The dose regimen formulation of doxycycline hydrochloride and florfenicol injection based on ex vivo pharmacokinetic-pharmacodynamic modeling against the Actinobacillus pleuropneumoniae in pigs[J].Animal Diseases,2023,3(4):286-298.

China Medical Abstracts(Internal Medicine)

2024年第1期

浏览历史

内容加载中请稍等...

Efficacy of different regimens and prognostic factors in patients with first relapsed multiple myeloma treated after front-line bortezomib,cyclophosphamide,and dexamethasone

相关作者

相关机构

相关主题

浏览历史